Abstract
As we have recently found a novel oncogene, the cancer-upregulated gene 2 (CUG2), which was elevated in a variety of tumor tissues such as the ovary, liver, lung and pancreas, we examined whether reovirus could efficiently induce cytolysis in cancer cells expressing CUG2 and thus be used as a potential cancer therapeutic agent. In this study, we describe experiments in which we use reovirus to treat NIH3T3 cells stably expressing either CUG2 (NIH-CUG2) or vector only (NIH-Vec). NIH-CUG2 cells readily support reoviral proliferation and undergo apoptosis, whereas NIH-Vec cells are highly resistant to reoviral infection and virus-induced apoptosis. This notable result may be explained by the observation that CUG2 expression inhibits PKR activation, leading to reoviral proliferation in nonpermissive NIH3T3 cells. Furthermore, reovirus infection results in almost complete regression of tumorgenic NIH-CUG2 cells in transplanted nude mice. As we found that CUG2 enhances activation of MAPK (ERK, JNK and p38), Src kinase and Ras, we examined whether CUG2 confers reoviral replication independent of the Ras or p38 MAPK signaling pathway. From these experiments we found that either inhibition of p38 MAPK or Ras blocks reoviral proliferation even in the presence of CUG2 but inhibition of ERK, JNK and Src kinase does not, indicating that activation of p38 MAPK and Ras has critical roles in reoviral replication in CUG2-expressing tumor cells. Accordingly, we propose that reovirus can be useful in the treatment of transformed cells expressing CUG2, which is commonly detected in various tumor tissues.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lee S, Gang J, Jeon SB, Choo SH, Lee B, Kim YG et al. Molecular cloning and functional analysis of a novel oncogene, cancer-upregulated gene 2 (CUG2). Biochem Biophys Res Commun 2007; 360: 633–639.
Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW . Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099–11104.
Kim M, Chung YH, Johnston RN . Reovirus and tumor oncolysis. J Microbiol 2007; 45: 187–192.
Rosen L, Evans HE, Spickard A . Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29–37.
Nibert ML, Schiff LA, Fields BN . Mammalian reoviruses contain a myristoylated structural protein. J Virol 1991; 65: 1960–1967.
Duncan MR, Stanish SM, Cox DC . Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978; 28: 444–449.
Hashiro G, Loh PC, Yau JT . The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307–315.
Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW . The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351–3362.
Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348–353.
Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–1334.
Norman KL, Lee PW . Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005; 10: 847–855.
Park EH, Koh SS, Srisuttee R, Cho IR, Min HJ, Jhun BH et al. Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Ther 2009; 16: 453–461.
Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561–8576.
Ring CJ . Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83 (Part 3): 491–502.
Russel FG, Masereeuw R, van Aubel RA . Molecular aspects of renal anionic drug transport. Annu Rev Physiol 2002; 64: 563–594.
Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M . Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx 2004; 31: 407–412.
Janssen HL, Higuchi H, Abdulkarim A, Gores GJ . Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003; 39: 414–420.
Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL . Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 2001; 20: 6910–6919.
Kim M, Egan C, Alain T, Urbanski SJ, Lee PW, Forsyth PA et al. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 2007; 26: 4124–4134.
Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C . Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929–7941.
Stewart MJ, Blum MA, Sherry B . PKR's protective role in viral myocarditis. Virology 2003; 314: 92–100.
Zhang P, Samuel CE . Protein kinase PKR plays a stimulus- and virus-dependent role in apoptotic death and virus multiplication in human cells. J Virol 2007; 81: 8192–8200.
Strong JE, Tang D, Lee PW . Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 1993; 197: 405–411.
Strong JE, Lee PW . The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996; 70: 612–616.
Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998; 58: 4947–4956.
Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962–972.
Fizazi K . The role of Src in prostate cancer. Ann Oncol 2007; 18: 1765–1773.
Marcato P, Shmulevitz M, Lee PW . Connecting reovirus oncolysis and Ras signaling. Cell Cycle 2005; 4: 556–559.
Park E-H, Koh SS, Ratakorn S, Cho I-R, Min H-J, Jhun BH et al. Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Therapy 2009; 16: 453–461.
Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW . Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007; 15: 1522–1530.
Smakman N, van den Wollenberg DJ, Borel Rinkes IH, Hoeben RC, Kranenburg O . Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 2005; 79: 14981–14985.
Acknowledgements
This work was supported by the World Class University program through NRF funded by Korean government (R31-2008-000-20004-0) to YHC and the Research Program for New Drug Target Discovery (M10748000195-08N4800-19510) grant from the Ministry of Science & Technology of Korea to SSK. This study was also supported by a grant of the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (00-PJ3-PG6-GN07-001) (BHJ).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Park, EH., Park, E., Cho, IR. et al. CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 17, 307–314 (2010). https://doi.org/10.1038/cgt.2009.83
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2009.83
Keywords
This article is cited by
-
Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling
Cellular Oncology (2017)
-
The oncolytic virus, pelareorep, as a novel anticancer agent: a review
Investigational New Drugs (2015)
-
Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling
Cancer Gene Therapy (2013)
-
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples
Modern Pathology (2012)